Treating Lupus with Benlysta
A few months ago, Human Genome Services Inc. (NASDAQ: HGSI) and co-development partner GlaxoSmithKline revealed data from a phase III trial of Benlysta™, a promising new drug for treating systemic lupus erythematosus (SLE), otherwise known as lupus. Their stock had literally tripled within a matter of two open trading sessions…



